<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11401310</article-id><article-id pub-id-type="pmc">2363687</article-id><article-id pub-id-type="pii">6691835</article-id><article-id pub-id-type="doi">10.1054/bjoc.2001.1835</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Somlo</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Doroshow</surname><given-names>J H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Synold</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Longmate</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Reardon</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chow</surname><given-names>W</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Forman</surname><given-names>S J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Leong</surname><given-names>L A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Margolin</surname><given-names>K A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jr</surname><given-names>R J Morgan</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Raschko</surname><given-names>J W</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Shibata</surname><given-names>S I</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tetef</surname><given-names>M L</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yen</surname><given-names>Y</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kogut</surname><given-names>N</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Schriber</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Alvarnas</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Departments of Medical Oncology and Therapeutics Research and Biostatistics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010</aff><aff id="aff2"><label>2</label>City of Hope Bone Marrow Transplant Unit/The Good Samaritan Hospital, Phoenix, AZ 85006</aff><aff id="aff3"><label>3</label>Regional Bone Marrow Transplantation Program, Southern California Kaiser Permanente, Los Angeles, CA, 90027, USA</aff><pub-date pub-type="ppub"><month>06</month><year>2001</year></pub-date><volume>84</volume><issue>12</issue><fpage>1591</fpage><lpage>1598</lpage><history><date date-type="received"><day>11</day><month>09</month><year>2000</year></date><date date-type="rev-recd"><day>19</day><month>02</month><year>2001</year></date><date date-type="accepted"><day>19</day><month>03</month><year>2001</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>We assessed the feasibility and pharmacokinetics of high-dose infusional paclitaxel in combination with doxorubicin, cyclophosphamide, and peripheral blood progenitor cell rescue. Between October 1995 and June 1998, 63 patients with high-risk primary [stage II with &#x02265; 10 axillary nodes involved, stage IIIA or stage IIIB inflammatory carcinoma (<italic>n</italic> = 53)] or with stage IV responsive breast cancer (<italic>n</italic> = 10) received paclitaxel 150&#x02013;775&#x02008;mg/m<sup>2</sup>infused over 24 hours, doxorubicin 165&#x02008;mg/m<sup>2</sup>as a continuous infusion over 96 hours, and cyclophosphamide 100&#x02008;mg kg<sup>&#x02013;1</sup>. There were no treatment-related deaths. Dose-limiting toxicity was reversible, predominantly sensory neuropathy following administration of paclitaxel at the 775&#x02008;mg/m<sup>2</sup>dose level. Paclitaxel pharmacokinetics were non-linear at higher dose levels; higher paclitaxel dose level, AUC, and peak concentrations were associated with increased incidence of paraesthesias. No correlation between stomatitis, haematopoietic toxicities, and paclitaxel dose or pharmacokinetics was found. Kaplan&#x02013;Meier estimates of 30-month event-free and overall survival for patients with primary breast carcinoma are 65&#x00025; (95&#x00025; CI; 51&#x02013;83&#x00025;) and 77&#x00025; (95&#x00025; CI; 64&#x02013;93&#x00025;). Paclitaxel up to 725&#x02008;mg/m<sup>2</sup>infused over 24 hours in combination with with doxorubicin 165&#x02008;mg/m<sup>2</sup>and cyclophosphamide 100&#x02008;mg kg<sup>&#x02013;1</sup>is tolerable. A randomized study testing this regimen against high-dose carboplatin, thiotepa and cyclophosphamide (STAMP V) is currently ongoing. &#x000a9; 2001 Cancer Research Campaign <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">http://www.bjcancer.com</ext-link></p></abstract></article-meta></front></article>


